Aciphex patent expiry – next week?

[Anonymous]

Generic Rabeprazole will be available as early as May 8, when the patent expires for Aciphex in the US. This is "the other shoe" dropping, after the loss of exclusivity of Aricept?

There doesn’t seem to be much in the commercial pipeline to make up for the 1-2 punch of losing Eisai's two blockbusters. I wonder how the company will readjust to deal with its dwindling revenue stream? More layoffs? Site closures?

 

[Anonymous]

Thats right you ass-effects turd rep, you got nothing. Your done.

 

[Anonymous]

6mo extension for pediatric trial - remember?

 

[Anonymous]

You're right. Sprinkle will save us!

 

[Anonymous]

From a May 7 Seeking Alpha article entitled "3 Bio Companies Facing The Patent Cliff"

Johnson & Johnson

Johnson & Johnson is another big pharmaceutical company that is expected to suffer a revenue loss amounting to $2.27 billion on account of two patents expiring in 2013. Aciphex, the heartburn medication that the company manufactures in partnership with the Japanese company Eisai (ESALF.PK), is likely to lose $860 million once it goes off patent. This is a small dent in a company of the size of Johnson & Johnson, with total annual revenue of $67.23 billion but Eisai's $1.1 billion revenue loss will have a great impact as the company has only six drugs selling in the U.S.

 

[Anonymous]

From a May 7 Seeking Alpha article entitled "3 Bio Companies Facing The Patent Cliff"

Johnson & Johnson

Johnson & Johnson is another big pharmaceutical company that is expected to suffer a revenue loss amounting to $2.27 billion on account of two patents expiring in 2013. Aciphex, the heartburn medication that the company manufactures in partnership with the Japanese company Eisai (ESALF.PK), is likely to lose $860 million once it goes off patent. This is a small dent in a company of the size of Johnson & Johnson, with total annual revenue of $67.23 billion but Eisai's $1.1 billion revenue loss will have a great impact as the company has only six drugs selling in the U.S.

two words, opt out

 

[Anonymous]

Generic Rabeprazole will be available as early as May 8, when the patent expires for Aciphex in the US. This is "the other shoe" dropping, after the loss of exclusivity of Aricept?

There doesn’t seem to be much in the commercial pipeline to make up for the 1-2 punch of losing Eisai's two blockbusters. I wonder how the company will readjust to deal with its dwindling revenue stream? More layoffs? Site closures?

First Hiroshima, second Nagasaki...history is repeating itself

 

[Anonymous]

Generic Rabeprazole will be available as early as May 8, when the patent expires for Aciphex in the US. This is "the other shoe" dropping, after the loss of exclusivity of Aricept?

There doesn’t seem to be much in the commercial pipeline to make up for the 1-2 punch of losing Eisai's two blockbusters. I wonder how the company will readjust to deal with its dwindling revenue stream? More layoffs? Site closures?

Look for 100 Tice Boulevard as a prime commercial property listing in the near future...

 

[Anonymous]

Generic Rabeprazole will be available as early as May 8, when the patent expires for Aciphex in the US. This is "the other shoe" dropping, after the loss of exclusivity of Aricept?

There doesn’t seem to be much in the commercial pipeline to make up for the 1-2 punch of losing Eisai's two blockbusters. I wonder how the company will readjust to deal with its dwindling revenue stream? More layoffs? Site closures?

What's frustrating is that "Purple Crack" pill will continue to sell as strong as it ever has in spite of a generic-laden market place.

 

[Anonymous]

Mazur said we will be OK with just Banzel.